The breast surgeon's role in BRCA1 and BRCA2 testing
1Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut 06520-8028, USA.
American Journal of Surgery
|December 13, 2000
Summary
Genetic testing for BRCA1/BRCA2 mutations is crucial for women with breast cancer. Results guide personalized cancer risk management and impact family member screening.
Area of Science:
- Oncology
- Genetics
- Hereditary Cancer Syndromes
Background:
- Hereditary mutations in BRCA1 or BRCA2 genes are found in 5-10% of breast cancer patients.
- Genetic testing is a clinically available tool with significant implications for patient management.
Purpose of the Study:
- To highlight the importance of genetic testing in managing breast and ovarian cancer risks.
- To emphasize the role of genetic testing in personalized cancer care and family risk assessment.
Main Methods:
- Review of current clinical practices and implications of genetic testing for BRCA1/BRCA2 mutations.
- Discussion of the impact of genetic testing on patient management and family risk.
Main Results:
- Genetic testing results significantly alter patient risks for primary breast and ovarian cancers.
- Test results influence surveillance, chemoprevention, and surgical decisions for at-risk individuals.
Conclusions:
- Genetic testing is integral to tailoring management plans for hereditary cancer syndromes.
- Surgeons play a key role in identifying at-risk patients, facilitating testing, and integrating results into care.
- Genetic testing results have implications for both the patient and their family members' cancer risks.
